Mark Ragosa - 01 Sep 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Sep 2022, 16:10:03 UTC
Prior SEC filing
28 Apr 2022
Next SEC filing
20 Mar 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Filing notes and source

Key filing fact

Mark Ragosa filed Form 4 for Kiniksa Pharmaceuticals, Ltd. (KNSA) on 06 Sep 2022.

Key facts

  • This page summarizes Mark Ragosa's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
  • 5 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 06 Sep 2022, 16:10.

Change

  • Previous filing in this sequence was filed on 28 Apr 2022.
  • Current net transaction value: -$6,258.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Common Share

Options Exercise

Transaction value
Shares
+1,861
Change %
+29%
Price
Shares after
8,218
Date
02 Sep 2022
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Common Share

Tax liability

Transaction value
-$6,258
Shares
-547
Change %
-6.7%
Price
$11.44
Shares after
7,671
Date
02 Sep 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value
$0
Shares
+64,660
Change %
Price
$0.000000
Shares after
64,660
Date
01 Sep 2022
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
64,660
Exercise price
$11.97
Footnotes
F2
KNSA transaction Derivative

Restricted Share Unit

Award

Transaction value
$0
Shares
+10,777
Change %
Price
$0.000000
Shares after
10,777
Date
01 Sep 2022
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
10,777
Exercise price
Footnotes
F1, F3
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
$0
Shares
-1,861
Change %
-25%
Price
$0.000000
Shares after
5,583
Date
02 Sep 2022
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
1,861
Exercise price
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Footnote F2

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.

Footnote F3

The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Footnote F4

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .